Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement

Overview of attention for article published in Frontiers in oncology, February 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter: 1 X user

facebook: 1 Facebook page

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 9 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 1 public wall post.

ALCASE Italia - Per la Lotta al Cancro del Polmone, 05 Mar 2022

Si tratta di una mutazione rara (riarrangiamento-RET), ma il farmaco che la combatte (PRALSETINIB: https://www.alcase.eu/farmaci…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.